| Features: | ||||||||||||||||||||||||||||||||||||||||||
| Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system, and its dysregulation has been implicated in Alzheimer’s disease (AD). -Altered GABA levels: Some studies report reduced GABA levels in the brain of AD patients, while others show compensatory increases in certain brain areas. Enhancing GABAergic signaling is being explored to: -Reduce neuronal hyperexcitability. -Alleviate agitation, anxiety, and seizure-like activity in AD. -Improve memory and cognition in early disease stages. -dietary sources of GABA. They include broccoli and other cruciferous vegetables, certain peas and beans, and oat, wheat, barley, rice, tomatoes, sweet potatoes, and spinach -GABA intake from dietary sources like tomatoes and fermented foods can be considerable -GABA, is synthesized from glutamate Cancer evidence status: No clinical evidence supports oral GABA supplements or GABA-enriched foods as cancer treatments. Experimental cancer studies primarily examine endogenous tumor GABA, GABA receptors, GABA-shunt metabolism, or direct exposure of cultured cells to GABA. Reported effects are bidirectional and highly tumor-dependent, including both growth inhibition and promotion of proliferation, invasion, metabolic adaptation, and immune suppression. These findings support GABAergic signaling as a mechanistic cancer target but do not establish supplemental GABA as an anticancer intervention. Alzheimer’s disease relevance: GABAergic dysfunction is significantly involved in Alzheimer’s disease, but it cannot be represented simply as a uniform GABA deficiency. Loss or dysfunction of inhibitory interneurons can reduce network inhibition, increase hippocampal hyperexcitability, disrupt gamma oscillations, and increase seizure susceptibility. Conversely, reactive astrocytes can produce excessive tonic GABA in affected regions, suppressing synaptic plasticity and memory circuits. The therapeutically relevant objective is restoration of spatially and receptor-subtype-specific excitation–inhibition balance rather than generalized enhancement of GABA signaling. Oral GABA is not an established Alzheimer’s disease treatment, has limited blood–brain barrier penetration, and lacks adequate randomized evidence for cognitive or disease-modifying benefit. Primary mechanisms (ranked):
Bioavailability / PK relevance: Endogenous brain GABA is locally synthesized and tightly compartmentalized. Supplemental GABA produces peripheral exposure but appears to cross an intact blood–brain barrier poorly. Increased oral intake therefore cannot be assumed to normalize cerebral GABA concentrations or selectively reach dysfunctional Alzheimer’s disease circuits. In-vitro vs systemic exposure relevance: Cell and animal studies using direct intracerebral delivery, receptor-selective drugs, genetic manipulation, or millimolar GABA exposure do not directly model ordinary dietary supplementation. Effects of selective GABA receptor modulators cannot be attributed automatically to oral GABA. Clinical evidence status: Mechanistic and animal evidence supports GABAergic pathways as Alzheimer’s disease targets, but direct oral GABA evidence is inadequate. Historical studies of GABAergic drugs and more recent receptor-selective approaches have not established GABA supplementation as a cognitive or disease-modifying therapy. Clinical status remains preclinical to exploratory human evidence. Alzheimer’s Disease Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: HalifaxProj(inhibit) |
| Type: |
| Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals. -Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis. -COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors. COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers. The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression: Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways. Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer. Drugs specifically targeting COX-2, such as celecoxib, have been developed. COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS. |
| 7080- | GABA, | The Effect of Oral GABA on the Nervous System: Potential for Therapeutic Intervention |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:342 Target#:66 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid